NewAmsterdam Pharma (NAMS) Payables (2022 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Payables for 4 consecutive years, with $9.0 million as the latest value for Q4 2025.
- Quarterly Payables rose 89.08% to $9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, up 89.08% year-over-year, with the annual reading at $9.0 million for FY2025, 89.08% up from the prior year.
- Payables hit $9.0 million in Q4 2025 for NewAmsterdam Pharma, down from $10.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $18.9 million in Q4 2022 to a low of $4.7 million in Q4 2024.
- Historically, Payables has averaged $10.0 million across 4 years, with a median of $10.0 million in 2024.
- Biggest five-year swings in Payables: tumbled 58.38% in 2024 and later surged 89.08% in 2025.
- Year by year, Payables stood at $18.9 million in 2022, then plummeted by 39.62% to $11.4 million in 2023, then crashed by 58.38% to $4.7 million in 2024, then soared by 89.08% to $9.0 million in 2025.
- Business Quant data shows Payables for NAMS at $9.0 million in Q4 2025, $10.1 million in Q3 2025, and $9.5 million in Q2 2025.